Citations

Clear

959 citation(s) found for "Service, F J".

Space Oncology: A Comprehensive Scoping Review
Niknam, Nafise , Akbarialiabad, Hossein , Kouhanjani, Mohsen Farjoud , Varghese, Lydia Johnson Kolaparambil , González, Amy Berrington de , Melin, M. Mark , Shafie’ei, Mohammad , Mousavi, Seyedeh Maryam , Hosseini, Seyed Ali , Taha, Seyed Reza , Grada, Ayman , Akbari, Zahra , Jokar-Derisi, Armita , Jurga, Marta , Das, Saswati , D’Urbano, Jessica , Hakim, Gabriella, Sadeghian, Najmeh , Tarbox, Michelle , West, Cameron , Hosseini, Seyed Hossein , Squire, Timothy , Christiansen, Rowena , Melin, Matthew M , Farjoud Kouhanjani, Mohsen , Kolaparambil Varghese, Lydia Johnson , Russomano, Thais , Murrell, D F , Leachman, Sancy A , Akbari, Zahra , Derisi, Armita Jokar , Das, Saswati , D'Urbano, Jessica , Hakim, Gabriella , Sadeghian, Najmeh , Paydar, Shahram , Tarbox, Michelle , West, Cameron , Ghorashi, Seyyed Mojtaba , Hosseini, Seyed Hossein , Squire, Timothy , Christiansen, Rowena , Berrington de Gonzalez, Amy , Leachman, Sancy A. , Kumar, Ajay , Bunick, Christopher G.

Mayo Clinic

Wilderness & Environmental Medicine | July 14, 2025 | Volume: 36 | Issue: 1_suppl | Pages: No page available

10.1177/10806032251349442 | PMID 40653854 Get It

Space exploration exposes astronauts to unique conditions such as microgravity and space radiation, potentially influencing gene expression and triggering carcinogenesis. Paradoxically, these extreme environments could uncover other pro-treatment aspects of cancer biology. Despite numerous reviews addressing these aspects in isolation, a comprehensive synthesis of the effects of space stressors on cancer development is incomplete. This scoping review aims to provide a holistic perspective on the influence of spaceflight and associated stressors—including gravitation (hyper- and microgravity), radiation, and vibration—on the potential for cancer development and altered cellular mechanisms. We adhered to the PRISMA-ScR checklist for our review. A multitiered search strategy was employed in English, starting with a preliminary keyword identification in Google Scholar and PubMed. Subsequently, the main search was conducted across five databases—Cochrane, Embase, PubMed, Scopus, and Web of Science—until 22 February 2024. All included studies were thoroughly assessed by two independent reviewers. Of the 15,553 identified articles, 158 were deemed eligible. The majority (92%) were experimental studies, predominantly cell-based (74.17%). Breast (15.19%), thyroid (13.92%), and hematopoietic (11.40%) cancers were the most frequently examined. Spaceflight stressors could affect different biological systems variably, with microgravity impacting spatial growth and metastasis, and cosmic radiation exerting both tumor-suppressive and mutagenic effects. Our findings highlight the need for large-scale, prolonged analog studies mimicking space conditions to enhance mission safety and shed light on the nuanced effects of space stressors on cancer. Additionally, further extensive studies need to be performed in the true weightlessness of spaceflight, both animal-based and on human tissue (cell cultures and potentially whole perfusion organ models), in addition to crew pre/intra/post-flight long-duration evaluations. Furthermore, this unique research avenue may reveal cancer cell sensitivities to these stressors, opening new pathways for innovative therapeutic strategies in cancer treatment.
Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline
Wyckoff, Jennifer , Lapolla, A., Asias-Dinh, Bernadette , Barbour, Linda A. , Brown, Florence M. , Catalano, Patrick , Corcoy, Rosa , Drobycki, Nancy, Kautzky‐Willer, Alexandra , Stephenson-Gray, Melanie, Tabák, Ádám G. , Weatherup, Emily, Zera, Chloe , Ospina, Naykky Singh , Wyckoff, Jennifer A , Kautzky-Willer, Alexandra , Murad, M Hassan , Tabák, Adam G , Lapolla, Annunziata, Renzo, Gian Carlo Di , Murad, M. Hassan

Mayo Clinic

European Journal of Endocrinology | July 13, 2025 | Volume: 193 | Issue: 1 | Pages: G1-G48

10.1093/ejendo/lvaf116 | PMID 40652450 Get It

Abstract Background Preexisting diabetes (PDM) increases the risk of maternal and perinatal mortality and morbidity. Reduction of maternal hyperglycemia prior to and during pregnancy can reduce these risks. Despite compelling evidence that preconception care (PCC), which includes achieving strict glycemic goals, reduces the risk of congenital malformations and other adverse pregnancy outcomes, only a minority of individuals receive PCC. Suboptimal pregnancy outcomes demonstrated in real-world data highlight the need to further optimize prenatal glycemia. New evolving technology shows promise in helping to achieve that goal. Dysglycemia is not the only driver of poor pregnancy outcomes in PDM. The increasing impact of obesity on pregnancy outcomes underscores the importance of optimal nutrition and management of insulin sensitizing medications during prenatal care for PDM. Objective To provide recommendations for the care of individuals with PDM that lead to a reduction in maternal and neonatal adverse outcomes. Methods The Guideline Development Panel (GDP) composed of a multidisciplinary panel of clinical experts, along with experts in guideline methodology and systematic literature review, identified and prioritized 10 clinically relevant questions related to the care of individuals with diabetes before, during and after pregnancy. The GDP prioritized randomized controlled trials (RCTs) evaluating the effects of different interventions (eg, PCC, nutrition, treatment options, delivery) during the reproductive life cycle of individuals with diabetes, including type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). Systematic reviews queried electronic databases for publications related to these 10 clinical questions. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology was used to assess the certainty of evidence and develop recommendations. The approach incorporated perspectives from 2 patient representatives and considered patient values, costs and resources required, acceptability and feasibility, and impact on health equity of the proposed recommendations. Results In individuals with diabetes mellitus who have the possibility of becoming pregnant, we suggest asking a screening question about pregnancy intention at every reproductive, diabetes, and primary care visit. Screening for pregnancy intent is also suggested at urgent care/emergency room visits when clinically appropriate (2 | ⊕OOO). This was suggested based on indirect evidence demonstrating a strong association between PCC and both reduced glycated hemoglobin (HbA1c) at the first prenatal visit and congenital malformations. In individuals with diabetes mellitus who have the possibility of becoming pregnant, we suggest use of contraception when pregnancy is not desired (2 | ⊕⊕OO). This was suggested based on indirect evidence in women with diabetes, where PCC—including contraception as a key component—showed a clinically significant association with improvements in first-trimester HbA1c and the rate of congenital malformations, together with indirect evidence from the general population regarding the reduction of unplanned pregnancies and pregnancy terminations with the use of contraception. In individuals with T2DM, we suggest discontinuation of glucagon-like peptide-1 receptor agonist (GLP-1RA) before conception rather than discontinuation between the start of pregnancy and the end of the first trimester (2 | ⊕OOO). This was suggested based on limited data on risk of exposure to GLP-1RA receptor agonists during pregnancy. In pregnant individuals with T2DM already on insulin, we suggest against routine addition of metformin (2 | ⊕OOO). This was suggested based on the GDP judgment that the benefit of adding metformin to insulin to achieve decrease in rates of large for gestational age infants did not outweigh the potential harm of increasing the risk of small for gestational age infants or adverse childhood outcomes related to changes in body composition. In individuals with PDM, we suggest either a carbohydrate-restricted diet (<175 g/day) or usual diet (>175 g/day) during pregnancy (2 | ⊕OOO). This was suggested based on the GDP judgment that the available evidence was limited and very indirect, resulting in significant uncertainty about the net benefits or harms. As such, the evidence was insufficient to support a recommendation either for or against a carbohydrate intake cutoff of 175 g/day. In pregnant individuals with T2DM, we suggest either the use of a continuous glucose monitor (CGM) or self-monitoring of blood glucose (SMBG) (2 | ⊕OOO). There is lack of direct evidence supporting superiority of CGM use over SMBG for T2DM during pregnancy. There is indirect evidence supporting improved glucometrics with the use of CGM for individuals with T2DM outside of pregnancy, substantial improvements in neonatal outcomes for individuals with T1DM using CGM during pregnancy and the potential for decreasing adverse pregnancy outcomes with improved glucometrics in individuals with T2DM. In individuals with PDM using a CGM, we suggest against the use of a single 24-hour CGM target <140 mg/dL (7.8 mmol/L) in place of standard-of-care pregnancy glucose targets of fasting <95 mg/dL (5.3 mmol/L), 1-hour postprandial <140 mg/dL (7.8 mmol/L), and 2-hour postprandial < 120 mg/dL (6.7 mmol/L) (2 | ⊕OOO). This was suggested based on indirect evidence that associated adverse pregnancy outcomes with a fasting glucose > 126 mg/dL (7 mmol/L). In individuals with T1DM who are pregnant, we suggest the use of a hybrid closed-loop pump (pump adjusting automatically based on CGM) rather than an insulin pump with CGM (without an algorithm) or multiple daily insulin injections with CGM (2 | ⊕OOO). This was suggested based on a meta-analysis of RCTs which demonstrated improvement in glucometrics with increased time in range (MD +3.81%; CI −4.24 to 11.86) and reduced time below range (MD −0.85%; CI −1.98 to 0.28) with the use of hybrid closed-loop pump technology. In individuals with PDM, we suggest early delivery based on risk assessment rather than expectant management (2 | ⊕OOO). This was suggested based on indirect evidence that risks may outweigh benefits of expectant management beyond 38 weeks gestation and that risk assessment criteria may be useful to inform ideal delivery timing. In individuals with PDM (including those with pregnancy loss or termination), we suggest postpartum endocrine care (diabetes management), in addition to usual obstetric care (2 | ⊕OOO). As the postpartum period frequently overlaps with preconception, this was suggested based on indirect evidence demonstrating a strong association between PCC and both reduced HbA1c at the first prenatal visit and congenital malformations. Conclusion The data supporting these recommendations were of very low to low certainty, highlighting the urgent need for research designed to provide high certainty evidence to support the care of individuals with diabetes before, during, and after pregnancy. Investment in implementation science for PCC is crucial to prevent significant mortality and morbidity for individuals with PDM and their children. RCTs to further define glycemic targets in pregnancy and refinement of emerging technology to achieve those targets can lead to significant reduction of harm and in the burden of diabetes care. Data on optimal nutrition and obesity management in pregnancy are lacking. More research on timing of delivery in women with PDM is also needed.
Ictal emotional features in pediatric and young adult patients with frontal lobe epilepsy
Tsai, Ming‐Chen , Fine, Anthony L. , Nickels, Katherine , Starnes, Keith , Wirrell, Elaine , Fine, Anthony , Nickels, Katherine C , Wirrell, Elaine C , Wong-Kisiel, Lily C. , Starnes, Donnie Keith , Lin, Ching‐Po , Wong‐Kisiel, Lily C.

Mayo Clinic

Epilepsia Open | July 12, 2025 | Volume: 10 | Issue: 5 | Pages: 1396-1403

10.1002/epi4.70097 | PMID 40650864 Get It

Abstract Objective To assess the localization and lateralization values of ictal emotional features and ictal defensive behaviors in pediatric and young adult patients with frontal lobe epilepsy (FLE). Methods Children and young adults with FLE were identified from a single institution's epilepsy surgery database. Two epileptologists determined by consensus the presence of ictal emotional features (positive‐ smile, laughter, humming, singing; negative‐ fear, crying, anger, disgust, contempt, sadness) and ictal defensive behaviors (freezing with a fearful facial expression, shielding the face with hands, burying the face in a pillow, or exhibiting hyperkinetic motor behaviors like attempting to escape from bed or resisting restraint) in each patient's first video EEG (vEEG). Historic seizure semiology and vEEG reports were compared with the consensus vEEG analysis. Longitudinal changes in ictal emotional features were defined by the emergence or resolution of ictal emotional features between historic seizure semiology and re‐review of presurgical vEEG analysis. Subgroup analyses were conducted according to the seizure lateralization (left vs. right) and sublobar localization (precentral, medial, lateral, extensive) based on surgical extent. Results Twenty‐three FLE patients were included (female 39%; mean age at vEEG analysis: 11.28 years, range 1.75–20.17). The inter‐rater reliability was very good for both ictal emotional features ( κ = 0.81, 95% CI: 0.59–1) and ictal defensive behaviors ( κ = 0.91, 95% CI: 0.79–1). Ictal emotional features were observed in 10 patients (43.4%), with negative emotions present in 70% (7/10) of these cases. vEEG reports lacked documentation of ictal emotional features in two patients. Although ictal emotional features showed no statistical correlation by sublobar regions, ictal defensive behaviors were consistently seen in medial compared to lateral FLE (100% vs. 16.6%; p = 0.004). Longitudinal changes in ictal emotional features were observed in 8 (34.7%) patients. Significance Ictal emotional features were common in pediatric and young adult FLE patients and were mainly negative. Ictal defensive behaviors were more likely associated with medial FLE. Longitudinal changes in ictal emotional features occurred in about a third of pediatric and young adult patients with FLE. Plain Language Summary This study examined emotional features and defensive behaviors during seizures in children and young adults with FLE. Negative emotions were commonly seen during seizures. Ictal defensive behaviors were more frequently observed in patients with medial FLE, and recognizing these signs could help clinicians localize the seizures. Changes in emotional features were seen over time in about one‐third of children and young adult patients.
Atomic-resolution structure of a chimeric Powassan tick-borne flavivirus
Das, Sayan , Narayanan, Anoop , Wang, Anqi , Moustafa, Ibrahim M. , Cho, Sung Hyun , Mitzel, Dana , Jose, Joyce , Hafenstein, Susan , Hafenstein, Susan L

Mayo Clinic

Science Advances | July 9, 2025 | Volume: 11 | Issue: 28 | Pages: No page available

10.1126/sciadv.adw7700 | PMID 40632869 Get It

Powassan virus (POWV) is an emerging tick-borne flavivirus for which no vaccine or antiviral treatment exists. The incidence of human infections of POWV in North America has been increasing because of the expanding distribution of the tick vector Ixodes scapularis that transmits POWV to humans. To mitigate the dangers of handling a risk group 3 human pathogen, a chimeric virus was constructed from the genetic backbone of a yellow fever virus vaccine strain 17D (YFV-17D) and the external structural proteins of POWV lineage II. The chimera had a comparable phenotype as POWV. The atomic resolution of yellow fever virus-Powassan virus chimera (yPOWV) structure was built without ambiguity, revealing surface glycans and lipid pocket factors. The similarity to other flavivirus structures and the phenotype similar to YFV-17D suggest that there could be future potential as a vaccine candidate.
AncestryGeni: a novel genetic ancestry classification pipeline for small and noisy sequence data
Elhaik, Eran , Behnamian, Sara , Howe, M. S., Tang, Hongwei , Yan, Huihuang , Tian, Shulan , Shivaram, Suganti, Mendoza, Cinthya Zepeda, Blaney, Patrick , Howe, Michael, Zepeda Mendoza, Cinthya, Maura, Francesco , Baughn, Linda B , Elhaik, Eran , Tian, Shulan , Blaney, Patrick , Howe, Michael, Zepeda‐Mendoza, Cinthya , Maclachlan, Kylee , Usmani, Saad Z. , Pirooznia, Mehdi , Morgan, Gareth J. , Maura, Francesco , Baughn, Linda B.

Mayo Clinic

Bioinformatics | July 8, 2025 | Volume: 41 | Issue: 7 | Pages: No page available

10.1093/bioinformatics/btaf391 | PMID 40627371 Get It

Abstract Motivation Efforts to address health disparities are often limited by the lack of robust computational tools for inferring genetic ancestry by calculating an individual’s genetic similarity to continental groups. We have already shown that a preferred alternative to self-described race is using ancestry-informative markers (AIMs) that can be classified into ancestral components and used to estimate their similarity to those of known populations to identify continental groups. However, real-world genomic data can present challenges, including limited availability of germline DNA, a small number of AIMs for each sample, and the use of different variant calling software, limiting the application of existing solutions. Results Here, we describe a novel supervised machine-learning tool AncestryGeni, which infers genetic ancestry for samples with even a hundred markers and is applicable to any genomic data, including whole exome sequencing (WES) and RNA sequencing (RNA-Seq) data. Applying AncestryGeni to a real-world genomic dataset obtained from the Multiple Myeloma Research Foundation (MMRF) CoMMpass study, we show that it is more accurate than the commonly used FastNGSadmix when using nonstandard genomic material. We also demonstrate that when using AncestryGeni, the tumor-derived sequence obtained from WES and RNA-Seq can be a robust data source to accurately estimate an individual’s genetic similarity to a continental group. Availability and implementation AncestryGeni pipeline is available at https://github.com/eelhaik/AncestryGeni/tree/main.
Multicenter Retrospective Study of Stereotactic Radiosurgery for Gynecological Cancer Brain Metastases
Billau, Mathilde Djeneba, Hamel, Andréanne, Tourigny, Jean-Nicolas, Iorio‐Morin, Christian , Niranjan, Ajay , Wei, Zhishuo , Lunsford, L. Dade , Jose, Shalini, Scanlon, Sydney, Mullen, Reed, Bernstein, Kenneth , Phuong, Christina , Sheehan, Jason P. , Pikis, Stylianos , Kosyakovsky, Jacob, Prasad, Rahul N. , Icaza, Denisse Arteaga, Cifarelli, Daniel T. , Wegner, Rodney E. , Shepard, Matthew J., Bowden, Gregory, Wandrey, Narine , Rusthoven, Chad G. , Hintz, Eric , Schulder, Michael , Goenka, Anuj , Peterson, Jennifer , Mathieu, David , Liščák, Roman , May, Jaromír , Luy, Diego D. , Silverman, Joshua S. , Kondziolka, Douglas , Peker, Selçuk , Samancı, Yavuz , Braunstein, Steve , Palmer, Joshua D. , Bailey, David, Zacharia, Brad E. , Cifarelli, Christopher P. , Mathieu, David

Mayo Clinic

Neurosurgery | July 7, 2025 | Volume: 98 | Issue: 1 | Pages: 194-203

10.1227/neu.0000000000003609 | PMID 40622139 Get It

BACKGROUND AND OBJECTIVES: Gynecological cancers represent 10% to 15% of cancers in women, but brain metastases (BM) are uncommon, with limited evidence regarding their management. This study investigates the role of stereotactic radiosurgery (SRS) for BM from primary gynecological cancers. METHODS: Institutions of the International Radiosurgery Research Foundation participated in this study. Inclusion criteria required histological diagnosis of epithelial ovarian, cervical, or endometrial cancer, SRS between 2000 and 2020, and at least 1 imaging or clinical follow-up. RESULTS: A total of 276 patients having SRS for 977 BM were included. Median age at SRS was 62 years (IQR, 55-70). Primary cancer origin was ovarian in 128 (46%), cervical in 43 (16%), and endometrial in 105 patients (38%). Median Karnofsky Performance Scale was 80%, and systemic disease was active in 124 (45%) of patients. A median of 1 metastasis was treated (IQR, 1-3) per patient. Median individual metastasis volume was 0.27 cc (IQR, 0.05-1.59 cc). The majority (91%) received single-fraction SRS, using a median margin dose of 18 Gy (IQR, 16-20 Gy). Actuarial overall survival was 77%, 65%, and 44% at 6, 12, and 24 months, respectively. Predictors of worsened survival included older age, cervical and endometrial primary, previous whole-brain radiation therapy (WBRT), active systemic disease, worsened Karnofsky Performance Scale, absence of subsequent surgery, and increasing number of BM. Actuarial local control was 94% at 6 months, 89% at 12 months, and 78% at 24 months. Previous SRS or WBRT, tumor bed treatment, and cervical histology increased the risk of local failure. New remote BM and leptomeningeal dissemination occurred in 44% and 11% of patients, respectively. Adverse radiation effects (ARE) occurred in 13% of cases but were symptomatic in only 3%. Previous WBRT or SRS and increased tumor diameter increased the risk of ARE. CONCLUSION: SRS is an effective management for BM from gynecological cancers with low risks of symptomatic ARE.
Refinement of day 28 treatment response criteria for acute GVHD: a collaboration study of the JSTCT and MAGIC
Akahoshi, Yu , Inamoto, Yoshihiro , Spyrou, Nikolaos , Diniz, Márcio A. , Ayuk, Francis , Choe, Hannah , Doki, Noriko , Eto, Tetsuya, Etra, Aaron , Holler, Ernst , Kawakita, Toshiro , Tanaka, Takashi , Vášová, Ingrid, Ishimaru, Fumihiko , Fukuda, Takahiro, Chen, Yi‐Bin , Nakamura, Ryotaro , Ferrara, James L.M. , Kanda, Yoshinobu , Diniz, Marcio A , Doki, Noriko , Hexner, Elizabeth , Hogan, William J , Tanaka, Takashi , Yoshihara, Satoshi , Ishimaru, Fumihiko , Chen, Yi-Bin , Kanda, Junya , Nakamura, Ryotaro , Atsuta, Yoshiko , Levine, John E , Teshima, Takanori , Akahoshi, Yu , Nakasone, Hideki , Asada, Noboru , Eto, Tetsuya , Hexner, Elizabeth O. , Hiramoto, Nobuhiro , Hogan, William J. , Kataoka, Keisuke , Tanaka, Masatsugu , Uchida, Naoyuki , Levine, John E.

Mayo Clinic

Blood Advances | July 1, 2025 | Volume: 9 | Issue: 18 | Pages: 4640-4653

10.1182/bloodadvances.2025016233 | PMID 40590886 Get It

Abstract Overall response (OR) that combines complete (CR) and partial responses (PR) is the conventional end point for acute graft-versus-host disease (GVHD) trials. Because PR includes heterogeneous clinical presentations, reclassifying PR could produce a better end point. Patients in the primary treatment cohort from the Japanese Society for Transplantation and Cellular Therapy (JSTCT) were randomly divided into training and validation sets. In the training set, a classification and regression tree algorithm generated day 28 refined response (RR) criteria based on symptoms at treatment and day 28. We then evaluated RR for primary and second-line treatments, using the area under the receiver operating characteristic curve (AUC) and negative predictive value (NPV) for 6-month nonrelapse mortality as performance measures. RR considered patients with grade 0/1 at day 28 without additional treatment as responders. RR for primary treatment produced higher AUCs than OR with small improvement of NPVs in both validation sets: JSTCT (AUC, 0.73 vs 0.69 [P < .001]; NPV, 92.0% vs 89.6% [P < .001]) and the Mount Sinai Acute GVHD International Consortium (MAGIC; AUC, 0.71 vs 0.68 [P = .032]; NPV, 90.9% vs 89.8% [P = .009]). RR for second-line treatment produced similar AUCs but much higher NPVs than OR in both validation sets of JSTCT (AUC, 0.64 vs 0.63 [P = .775]; NPV, 74.5% vs 66.0% [P < .001]) and MAGIC (AUC, 0.67 vs 0.64 [P = .105]; NPV, 86.8% vs 76.1% [P = .004]). Classifying persistent but mild skin symptoms as responses and residual lower gastrointestinal GVHD as nonresponses were major drivers in improving the prognostic performance of RR. Our externally validated day 28 RR would serve as a better end point than conventional criteria in future first- and second-line treatment trials.
The contemporary management of prostate cancer
Chakrabarti, Deep , Albertsen, Peter C. , Adkins, Aidan, Kishan, Amar U. , Murthy, Vedang, Parker, Chris, Pathmanathan, Angela, Reid, Alison , Sartor, Oliver, Walz, Jochen , Tree, Alison , Walz, Jochen , Tree, Alison C , As, Nicholas van

Mayo Clinic

CA: A Cancer Journal for Clinicians | June 27, 2025 | Volume: 75 | Issue: 6 | Pages: 552-586

10.3322/caac.70020 | PMID 40572035 Get It

Abstract Prostate cancer is the most common cancer in two thirds of the world, with an expected doubling in both incidence and mortality in the next two decades. No strong environmental associations exist for the development of prostate cancer; therefore, lifestyle measures are unlikely to mitigate this increasing burden. The last three decades have seen rapid developments in the diagnostic and therapeutic landscape of prostate cancer, including multiparametric magnetic resonance imaging, positron emission tomography, robotic surgery, image‐guided hypofractionated and stereotactic radiotherapy, novel anti‐androgens and radioligand therapies. Prostate cancer is unique in that not everyone with a diagnosis needs treatment, and active surveillance is the preferred option for some. This review discusses the contemporary management of all stages of prostate cancer in the light of these modern developments, enabling holistic individualization of treatment, and describes the promise of future research to further improve outcomes.
A curriculum for epilepsy surgery: A report from the Surgical Commission's Epilepsy Surgery Educational Task Force and the Educational Council of the ILAE
Dorfer, Christian , Enslin, Nico , Olivera, Tatiana von Hertwig Fernandes de, Wiebe, Samuel , Alotaibi, Faisal , Ali, Rushna , Englot, Dario J. , Cross, J. Helen , Ali, Rushna P, Dorfer, Christian , Englot, Dario J , Cross, Helen J , Nico Enslin, Johannes M , Muh, Carrie R. , Wang, Xiongfei , Wiebe, Samuel , McKhann, Guy M. , Damisah, Eyiyemisi C. , Singh, Gagandeep , Blümcke, Ingmar , Rydenhag, Bertil , Alonso‐Vanegas, Mario , Cukiert, Arthur

Mayo Clinic

Epileptic Disorders | June 26, 2025 | Volume: 27 | Issue: 5 | Pages: 718-728

10.1002/epd2.70054 | PMID 40569634 Get It

Abstract Objective There is a need to develop a comprehensive, formalized, and globally applicable epilepsy surgery curriculum in order to help standardize the quality of epilepsy surgery practice in the world. Methods The Epilepsy Surgery Educational Task Force of the ILAE developed a competency‐based epilepsy surgery educational curriculum comprised of four domains: Diagnosis, Counseling, Pre‐surgical Work‐up, and Surgical Techniques. To evaluate this educational curriculum, a survey questionnaire consisting of 11 items was sent out for feedback to ILAE and IESS members. The survey questionnaire asked respondents to rate the degree of importance of each competency on a five‐point scale that ranged from “extremely important” to “not at all important” and provided space for free text comments. All competencies that were rated as “slightly important” or “somewhat important” by more than 10% of responders, as well as all free text feedback comments, were fully reviewed, and the final curriculum was adjusted accordingly. Results One hundred and twenty‐two responses ( n = 122) were submitted by the ILAE and IESS communities. Seventy‐one percent (71.9%) of the responses came from neurosurgeons of varied experience and training levels. Ninety‐four percent (94.4%) of responders stated that they “support a curriculum to determine the competency of neurosurgeons participating in the care of people with epilepsy in my country,” and 94.3% confirmed that they “would be interested in taking or would recommend an ILAE course based on these competencies, that would provide an ILAE certificate of completion.” Relevant changes within the curriculum were made based on feedback. Significance The newly developed ILAE comprehensive epilepsy surgery educational curriculum has a high level of support from neurosurgeons and neurologists around the world and shows potential for broad acceptance and implementation.
Efficacy and safety of thrombolysis for pediatric venous thromboembolism: a systematic review and meta-analysis
Kawtharany, Hassan , Azzam, Muayad , Alkhader, Aseel, Betensky, Marisol , Hamarsha, Qais, Mansour, Razan , Tabak, Carine , Bhat, Rukhmi , Biss, Tina , Brandão, Leonardo R. , Chan, Anthony K.C. , Faustino, E. Vincent S. , Jaffray, Julie , Jones, Sophie , Kerlin, Bryce A. , Pelland‐Marcotte, Marie‐Claude , Raulji, Chittalsinh M , Sartain, Sarah E. , Ommen, C. Heleen van , Wiernikowski, John , Williams, Suzan , Wilson, Hope P. , Woods, Gary , Zia, Ayesha , Abou Zeid, Hadi K, Brandão, Leonardo R , Chan, Anthony K C , Jaffray, Julie , Jones, Sophie , Kerlin, Bryce A , Kucine, Nicole , Male, Christoph , Pelland-Marcotte, Marie-Claude , Raffini, Leslie , Raulji, Chittalsinh M , Tarango, Cristina , van Ommen, C Heleen , Velez, Maria C , Vesely, Sara K , Zia, Ayesha , Monagle, Paul , Mustafa, Reem A , Kawtharany, Hassan , Hamarsha, Qais , Zeid, Hadi Khaled Abou , Patel, Payal Mukesh , Baghdadi, Sarah L., Bercovitz, Rachel S. , Branchford, Brian R. , Kumar, Riten , Takemoto, Clifford M.

Mayo Clinic

Blood Advances | June 25, 2025 | Volume: 9 | Issue: 21 | Pages: 5512-5527

10.1182/bloodadvances.2025017058 | PMID 40561511 Get It

Abstract We conducted this systematic review to evaluate outcomes of thrombolysis followed by anticoagulation vs anticoagulation alone in pediatric patients with venous thromboembolism (VTE). This systematic review addresses mortality, VTE resolution, recurrence, bleeding, and organ-specific outcomes in 5 PICO (population, intervention, comparison, outcomes) questions on thrombolysis across pulmonary embolism (PE), extremity deep vein thrombosis (DVT), right atrial thrombosis (RAT), cerebral sinus venous thrombosis (CSVT), and renal vein thrombosis (RVT). Meta-analysis reported risk ratios or differences (95% confidence intervals [CIs]), and absolute effects per 1000 patients. Certainty of evidence was assessed using GRADE (Grading of recommendation, assessment, Development, and Evaluation) guidelines. Thirteen nonrandomized studies were included and no randomized clinical trials addressed these questions. Thrombolysis might be associated with a higher risk of major bleeding, clinically relevant nonmajor bleeding, or unspecified bleeding with risk differences of 0.09 (95% CI, −0.06 to 0.23), 0.06 (95% CI, −0.11 to 0.22), and 0.09 (95% CI, −0.04 to 0.23), respectively. In PE with hemodynamic compromise, thrombolysis might be associated with a lower risk of mortality but conclusions on PE progression were uncertain in submassive PE. In DVT, thrombolysis may have little to no effect on mortality or thrombus resolution but might be associated with lower risk of postthrombotic syndrome. In RAT, thrombolysis might have little to no effect on thrombus resolution but a higher risk of major bleeding and mortality. For CSVT and RVT, the evidence was very limited. These findings were based on very-low-certainty evidence because of confounding and imprecision from small sample sizes. This systematic review highlights key challenges in developing recommendations for thrombolysis in children with VTE.